ATARA BIOTHERAPEUTICS, INC. (ATRA) Operating Margin
- Operating margin · 12 months: Value -229.67%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -229.67% | Operating income / revenue. Period ending 2026-06-30. $-14.23M ÷ $6.19M × 100 ≈ -229.67% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -14.23M USD | Operating Income (Loss) |
| Revenue | 6.19M USD | |
| Cost of products and services | (m) | |
| Research and development | 4.21M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-14.23M | $6.19M | (m) | $4.21M | (m) | -229.67% |
| 2026-03-31 | $-6.31M | $23.14M | (m) | $10.18M | (m) | -27.27% |
| 2025-12-31 | $35.86M | $120.77M | (m) | $37.45M | (m) | 29.69% |
| 2025-09-30 | $26.22M | $151.93M | (m) | $66.39M | (m) | 17.26% |
| 2025-06-30 | $8.04M | $188.67M | (m) | $107.39M | (m) | 4.26% |
| 2025-03-31 | $-13.39M | $199.73M | (m) | $133.41M | (m) | -6.70% |
| 2024-12-31 | $-83.44M | $128.94M | (m) | $151.48M | (m) | -64.71% |
| 2024-09-30 | $-131.20M | (m) | (m) | $172.36M | (m) | (m) |
| 2024-06-30 | $-179.05M | (m) | (m) | $185.33M | (m) | (m) |
| 2024-03-31 | $-232.24M | (m) | (m) | $208.13M | (m) | (m) |
| 2023-12-31 | $-276.01M | (m) | (m) | $224.78M | (m) | (m) |
| 2023-09-30 | $-291.58M | (m) | (m) | $237.70M | (m) | (m) |
| 2023-06-30 | $-306.59M | (m) | (m) | $250.97M | (m) | (m) |
| 2023-03-31 | $-267.31M | (m) | (m) | $259.73M | (m) | (m) |
| 2022-12-31 | $-280.51M | (m) | (m) | $272.53M | (m) | (m) |
| 2022-09-30 | $-298.38M | (m) | (m) | $289.15M | (m) | (m) |
| 2022-06-30 | $-298.57M | (m) | (m) | $289.33M | (m) | (m) |
| 2022-03-31 | $-350.44M | (m) | (m) | $292.90M | (m) | (m) |
| 2021-12-31 | $-340.46M | (m) | (m) | $282.00M | (m) | (m) |
| 2021-09-30 | $-328.76M | (m) | (m) | $268.42M | (m) | (m) |
| 2021-06-30 | $-318.65M | (m) | (m) | $257.96M | (m) | (m) |
| 2021-03-31 | $-312.60M | (m) | (m) | $251.05M | (m) | (m) |
| 2020-12-31 | $-309.05M | (m) | (m) | $244.65M | (m) | (m) |
| 2020-09-30 | $-307.05M | (m) | (m) | $240.74M | (m) | (m) |
| 2020-06-30 | $-304.90M | (m) | (m) | $234.40M | (m) | (m) |
| 2020-03-31 | $-302.49M | (m) | (m) | $225.09M | (m) | (m) |
| 2019-12-31 | $-295.68M | (m) | (m) | $216.10M | (m) | (m) |
| 2019-09-30 | $-297.80M | (m) | (m) | $216.71M | (m) | (m) |
| 2019-06-30 | $-285.46M | (m) | (m) | $206.53M | (m) | (m) |
| 2019-03-31 | $-262.55M | (m) | (m) | $187.66M | (m) | (m) |
| 2018-12-31 | $-237.11M | (m) | (m) | $167.46M | (m) | (m) |
| 2018-09-30 | $-191.10M | (m) | (m) | $129.97M | (m) | (m) |
| 2018-06-30 | $-162.54M | (m) | (m) | $107.22M | (m) | (m) |
| 2018-03-31 | $-137.82M | (m) | (m) | $92.13M | (m) | (m) |
| 2017-12-31 | $-121.53M | (m) | (m) | $81.21M | (m) | (m) |
| 2017-09-30 | $-104.48M | (m) | (m) | $69.91M | (m) | (m) |
| 2017-06-30 | $-98.77M | (m) | (m) | $68.11M | (m) | (m) |
| 2017-03-31 | $-90.34M | (m) | (m) | $62.81M | (m) | (m) |
| 2016-12-31 | $-81.24M | (m) | (m) | $56.51M | (m) | (m) |
| 2016-09-30 | $-84.26M | (m) | (m) | $19.65M | (m) | (m) |
| 2016-06-30 | $-70.58M | (m) | (m) | $8.96M | (m) | (m) |
| 2016-03-31 | $-66.20M | (m) | (m) | $7.48M | (m) | (m) |
| 2015-12-31 | $-58.45M | (m) | (m) | $2.00M | (m) | (m) |
| 2015-09-30 | $-47.27M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-40.96M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-30.39M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-28.16M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-8.62M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |